These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1292305)

  • 1. Hydroxyurea for the treatment of sickle cell disease.
    el-Hazmi MA; Warsy AS; al-Momen A; Harakati M
    Acta Haematol; 1992; 88(4):170-4. PubMed ID: 1292305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacological manipulation of fetal haemoglobin: trials using hydroxyurea and recombinant human erythropoietin.
    el-Hazmi MA; al-Momen A; Warsy AS; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F
    Acta Haematol; 1995; 93(2-4):57-61. PubMed ID: 7543719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
    el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
    Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal doses of hydroxyurea for sickle cell disease.
    Lima CS; Arruda VR; Costa FF; Saad ST
    Braz J Med Biol Res; 1997 Aug; 30(8):933-40. PubMed ID: 9361721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience.
    Youssry I; Abdel-Salam A; Ismail R; Bou-Fakhredin R; Mohamed Samy R; Ezz El-Deen F; Taher AT
    Hemoglobin; 2017; 41(4-6):267-273. PubMed ID: 29251012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea and erythropoietin therapy in sickle cell anemia.
    Goldberg MA; Brugnara C; Dover GJ; Schapira L; Lacroix L; Bunn HF
    Semin Oncol; 1992 Jun; 19(3 Suppl 9):74-81. PubMed ID: 1379376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of sickle cell anemia with hydroxyurea and erythropoietin.
    Goldberg MA; Brugnara C; Dover GJ; Schapira L; Charache S; Bunn HF
    N Engl J Med; 1990 Aug; 323(6):366-72. PubMed ID: 1695325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients.
    Al-Nood HA; Al-Khawlani MM; Al-Akwa A
    Hemoglobin; 2011; 35(1):13-21. PubMed ID: 21250877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
    Al-Jam'a AH; Al-Dabbous IA
    Saudi Med J; 2002 Mar; 23(3):277-81. PubMed ID: 11938415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea in the treatment of sickle-cell anemia.
    Howard LW; Kennedy LD
    Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
    Ballas SK; McCarthy WF; Guo N; Brugnara C; Kling G; Bauserman RL; Waclawiw MA
    Hemoglobin; 2010; 34(5):424-9. PubMed ID: 20854115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo.
    Ballas SK; Dover GJ; Charache S
    Am J Hematol; 1989 Oct; 32(2):104-11. PubMed ID: 2757007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of hydroxyurea in decreasing the occurrence of vasso-occulusive crisis in pediatric patients with sickle cell disease at King Saud Medical City in Riyadh, Saudi Arabia.
    Azmet FR; Al-Kasim F; Alashram WM; Siddique K
    Saudi Med J; 2020 Jan; 41(1):46-52. PubMed ID: 31915794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.
    Keikhaei B; Yousefi H; Bahadoram M
    Glob J Health Sci; 2015 Aug; 8(3):252-6. PubMed ID: 26493428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxyurea therapy in UK children with sickle cell anaemia: A single-centre experience.
    Phillips K; Healy L; Smith L; Keenan R
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28988427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea.
    Ballas SK; Marcolina MJ; Dover GJ; Barton FB
    Br J Haematol; 1999 May; 105(2):491-6. PubMed ID: 10233426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey.
    Colombatti R; Palazzi G; Masera N; Notarangelo LD; Bonetti E; Samperi P; Barone A; Perrotta S; Facchini E; Miano M; Del Vecchio GC; Guerzoni ME; Corti P; Menzato F; Cesaro S; Casale M; Rigano P; Forni GL; Russo G; Sainati L;
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28868627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular effects of hydroxyurea in Hb SC disease.
    Steinberg MH; Nagel RL; Brugnara C
    Br J Haematol; 1997 Sep; 98(4):838-44. PubMed ID: 9326175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
    Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.